ProstaMine was applied to NKX3-1-loss and RB1-loss tumors and identified co-altered genes that function in canonical PCa signaling pathways including MAPK, NF-kB, p53, SMAD, and PI3K. This evidence concerns the gene NKX3-1 and posterior cortical atrophy.